Amgen receives complete response letter for denosumab indication - ModernMedicine

The FDA recently issued a complete response letter for Amgen Inc.’s supplemental Biologics License Application for the RANK ligand inhibitor denosumab (XGEVA) to treat men with castration-resistant prostate cancer at high risk of developing ...

Osteoporosis Drug Market- Global And China Market Analysis - PR-USA.net

Amgen’s Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with the ...

FDA denies Amgen's request to expand denosumab sales - Daily Camera

THOUSAND OAKS, Calif. -- The Food and Drug Administration has denied Amgen permission to expand the sale of its denosumab drug, under the brand name Xgeva, to male patients with prostate cancer. Specifically, the use of the drug that was ...

Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015) - Yahoo Finance

Amgen's Denosumab is the recent entrant to the Osteoporosis treatment market, following its approval from the U.S. and European Union (also approved for bone loss associated with prostate cancer). Denosumab is expected to compete directly with ...

Prolia May Lead to Adverse Skin Side Effects - cisionwire.com

More than 40 serious adverse effects on the skin have been linked to the osteoporosis drug Prolia (denosumab), according to a review of Food and Drug Administration records by investigators. The records include people experiencing conditions ...

New cancer drugs given approval - Sunderland Echo

Of the drugs, Rituximab, which treats cancer of the blood, is being funded through primary care trust budgets with the others – Vemurafenib, Denosumab, Eribulin and Bevacizumab (Avastin) – being paid for by the cancer drug fund allocation from the Government.

Amgen Presents Oncology Data - Analyst Blog - NASDAQ

In addition to presenting data on blinatumomab and rilotumumab, Amgen will present data on talimogene laherparepvec (T-VEC), AMG 386 as well as denosumab among others.

Aging Population, Growing Awareness and Novel Therapeutics Drives the Global Osteoporosis … - YAHOO! - YAHOO!

Growth in the market is also expected to be driven by the recent approval of Denosumab, a monoclonal antibody recently approved for the treatment of osteoporosis. Denosumab has been approved in the US, EU, Switzerland, Canada, and Australia. In the ...

Emerging Insights into the Role of the Skeleton - Genetic Engineering News

Because they are highly effective and specific for bone, these potent agents—for example the recently approved denosumab—are not only indicated for postmenopausal osteoporosis in women at high risk of fracture but also as a treatment in men to increase ...

Amgen Receives Complete Response Letter From FDA for XGEVA® sBLA for Prevention of Bone Metastases - Boston Globe

April 26, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab ...